American Association for Cancer Research
15357163mct140256-sup-129026_1_supp_2529394_n7jcvl.pdf (2.42 MB)

Supplementary Figures S1-S3 from Small Molecule BMH-Compounds That Inhibit RNA Polymerase I and Cause Nucleolar Stress

Download (2.42 MB)
journal contribution
posted on 2023-04-03, 14:21 authored by Karita Peltonen, Laureen Colis, Hester Liu, Sari Jäämaa, Zhewei Zhang, Taija af Hällström, Henna M. Moore, Paul Sirajuddin, Marikki Laiho

Supplementary Figures S1-S3. Supplementary Figure 1. BMH-9, BMH-22 and BMH-23 cause a reduction in RPA194 half life. Supplementary Figure 2. BMH-9, BMH-22 and BMH-23 do not activate the DNA damage response. Supplementary Figure 3. p53 activation by Nutlin-3 does not affect the integrity of the nucleolus or rRNA synthesis.



Activation of the p53 pathway has been considered a therapeutic strategy to target cancers. We have previously identified several p53-activating small molecules in a cell-based screen. Two of the compounds activated p53 by causing DNA damage, but this modality was absent in the other four. We recently showed that one of these, BMH-21, inhibits RNA polymerase I (Pol I) transcription, causes the degradation of Pol I catalytic subunit RPA194, and has potent anticancer activity. We show here that three remaining compounds in this screen, BMH-9, BMH-22, and BMH-23, cause reorganization of nucleolar marker proteins consistent with segregation of the nucleolus, a hallmark of Pol I transcription stress. Further, the compounds destabilize RPA194 in a proteasome-dependent manner and inhibit nascent rRNA synthesis and expression of the 45S rRNA precursor. BMH-9– and BMH-22–mediated nucleolar stress was detected in ex vivo–cultured human prostate tissues indicating good tissue bioactivity. Testing of closely related analogues showed that their activities were chemically constrained. Viability screen for BMH-9, BMH-22, and BMH-23 in the NCI60 cancer cell lines showed potent anticancer activity across many tumor types. Finally, we show that the Pol I transcription stress by BMH-9, BMH-22, and BMH-23 is independent of p53 function. These results highlight the dominant impact of Pol I transcription stress on p53 pathway activation and bring forward chemically novel lead molecules for Pol I inhibition, and, potentially, cancer targeting. Mol Cancer Ther; 13(11); 2537–46. ©2014 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager